Hepatitis/MASH

Zepatier is already approved in the United States and Canada for treatment of hepatitis C.

CDC raises concerns about mother-to-child transmission of hepatitis C virus.

Jennifer Andres, PharmD, BCPS, clinical assistant professor of pharmacy practice at Temple University School of Pharmacy discusses the sorts of services pharmacists can provide for hepatitis C patients.

Jennifer Andres, PharmD, BCPS, clinical assistant professor of pharmacy practice at Temple University Schools of pharmacy describes how hepatitis C care in the pharmacy differs from care provided in other settings.

Veikira XR is a once-daily medication that treats hepatitis C genotype 1.

Veikira XR is a once-daily medication that treats hepatitis C genotype 1.

The United States was found to have higher prescription and surgery costs compared with other countries.

Specialty pharmacists play an important role in making evidence-based recommendations for the treatment of hepatitis C virus.

Is the cost of specialty drugs worth the price in small patient populations?

Patients treated with HCV drugs prior to transplant found to have higher overall post-transplant care costs.

Restricted access to antiviral HCV treatments only reduces spending in the short-term.

Positive relationship found between the pricing of HCV drug regimens with the rate of sustained viral response.

Restrictions begin to lift for high cost hepatitis C drugs.

Restricted access to antiviral HCV treatments only reduces spending in the short-term.

Four major hepatitis genotypes kill more people than HIV, malaria, and tuberculosis.

Top news of the day from across the health care landscape.

Threat of legal action prompts several states to allow greater access to curative HCV drugs.

Top news of the day from across the health care landscape.

Approximately 58% of patients with nonalcoholic steatohepatitis treated with pioglitazone showed reduced disease activity.

Nonalcoholic fatty liver disease is the buildup of extra fat in the liver that isn't caused by alcohol abuse.

Specific blood-born microRNAs mutate before the development of hepatocellular carcinoma.

Liver cancer cells died when the AURKA-MYC interaction was inhibited.

Top news of the day from across the health care landscape.

While cancer spending contributes largely to medical spending, it only accounted for 6.3% of growth from 2000 to 2012.

Epclusa is the first drug approved to treat all 6 major genotypes of hepatitis C virus.

Epclusa showed up to 99% viral suppression after 12 weeks across major hepatitis C genotypes.

Some injection drug users with HIV and hepatitis C seem to have the same immune problems as the elderly.

The FDA today approved Gilead Sciences' sofosbuvir and velpatasvir (Epclusa) for the treatment of adult patients with chronic hepatitis C virus both with and without cirrhosis.

Researchers evaluate the link between organ transplant and the increased likelihood of developing diabetes.

Insurers have taken interest in outcomes-based contracts for specialty drugs and non-specialty drugs.